These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7924892)

  • 1. Effects of drug manipulations on anterior components of somatosensory evoked potentials in a parkinsonian animal model.
    Onofrj M; Ferracci F; Fulgente T; Malatesta G; Ghilardi MF
    Drugs Exp Clin Res; 1994; 20(1):29-36. PubMed ID: 7924892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of the early anterior negativity of median nerve somatosensory evoked potential in the MPTP-treated monkey.
    Onofrj M; Ghilardi MF; Basciani M; Martinez-Tica J; Glover A
    Neurophysiol Clin; 1990 Oct; 20(4):283-93. PubMed ID: 2290412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients.
    de Mari M; Margari L; Lamberti P; Iliceto G; Ferrari E
    J Neural Transm Suppl; 1995; 45():171-6. PubMed ID: 8748623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
    Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
    Schneider JS; Pope-Coleman A; Van Velson M; Menzaghi F; Lloyd GK
    Mov Disord; 1998 Jul; 13(4):637-42. PubMed ID: 9686767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
    Traversa R; Pierantozzi M; Semprini R; Loberti M; Cicardi MC; Bassi A; Stanzione P
    J Neural Transm Suppl; 1995; 45():177-85. PubMed ID: 8748624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 128-channel somatosensory evoked potentials in the differential diagnosis of parkinsonian disorders.
    van de Wassenberg WJ; van der Hoeven JH; Leenders KL; Maurits NM
    Parkinsonism Relat Disord; 2009 Sep; 15(8):564-71. PubMed ID: 19303347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
    Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C
    Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
    Nevet A; Morris G; Saban G; Fainstein N; Bergman H
    J Neurophysiol; 2004 Oct; 92(4):1973-81. PubMed ID: 15115785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.